# Tern appoints Jane McCracken & Iain Ross as independent Non-Executive Directors

- Link: https://www.directorstalkinterviews.com/tern-appoints-jane-mccracken-iain-ross-as-independent-non-executive-directors/4121175894
- Published: 2024-10-29T07:22:00+00:00
- Author: Amilia Stone

**[Tern Plc](https://www.directorstalkinterviews.com/company/tern-plc/tern.l) **(
[LON:TERN](https://www.directorstalkinterviews.com/company/tern-plc/tern.l)), the
investment company specialising in supporting high growth, early-stage, disruptive
Internet of Things (IoT) technology businesses, has announced a number of changes
to the Company’s Board of Directors.  Tern is pleased to announce the appointment
of Jane Karwoski (known as “Jane McCracken”) and Iain Ross as independent Non-Executive
Directors of the Company with immediate effect.  Sarah Payne and Alan Howarth have
stepped down from the Board with immediate effect to concentrate on their other 
business interests.

Following these changes the Board now comprises Ian Ritchie (Non-Executive Chairman),
Jane McCracken (Non-Executive Director) and Iain Ross (Non-Executive Director).

Jane McCracken has spent her career working with high growth technology businesses
based in the USA. UK and Europe as an entrepreneur, investor, board member and advisor.
Her experience covers a variety of areas including software, e-commerce, digital
health and clinical research.  She recently served as an Entrepreneur-in-Residence
at the Advanced Technology Development Center, the state incubator based at Georgia
Institute of Technology.  She is the Chief Growth Officer for Corps Team, a US-based
search and staffing firm supporting startups to the Fortune 500.  Jane also serves
on the board of London Stock Exchange Main Market listed Edinburgh Worldwide Investment
Trust plc, which invests globally in high growth companies; and Radyus Research,
a US-based privately held company that advises on drug discovery, lead candidate
selection, and enabling studies.

Iain Ross has over 40 years’ experience in the international life sciences and technology
sectors and has held significant roles in multi-national pharmaceutical and biotech
companies.  He has completed multiple financing transactions and has over 30 years’
experience in cross-border management as a chairman or CEO.  He has led or participated
in eight IPOs and has direct experience of M&A transactions in Europe, the USA and
the Pacific Rim.  Currently he is Chairman of NASDAQ listed Silence Therapeutics
plc, Executive Chairman of ReNeuron Group plc and internationally holds other non-
executive director roles. 

Further information on Jane McCracken and Iain Ross disclosed in accordance with
Rule 17 and Schedule 2(g) of the AIM Rules for Companies is set out below.

> **Commenting, Ian Ritchie, Chairman of Tern, said:** “_I am delighted to welcome
> Jane and Iain to the Tern Board.  I believe their skills and experience will be
> invaluable as we focus on generating returns for our shareholders from realisations.
> I would also like to take this opportunity to thank Sarah and Alan for their significant
> contributions to Tern and wish them well for the future.”_

Share on:
